BPMC - Blueprint Medicines  GAAP EPS of -$2.19 revenue of $57.6M

2023-08-02 07:16:09 ET

• Blueprint Medicines press release ( NASDAQ: BPMC ): Q2 GAAP EPS of -$2.19.
• Revenue of $57.6M (+57.6% Y/Y).
• Cost of Sales: Cost of sales was $2.3 million for the second quarter of 2023, as compared to $4.9 million for the second quarter of 2022.
• Net Loss: Net loss was $132.8 million for the second quarter of 2023, or a net loss per share of $2.19, as compared to a net loss of $159.7 million for the second quarter of 2022, or a net loss per share of $2.68.
• Cash Position: As of June 30, 2023, cash, cash equivalents and investments were $836.6 million, as compared to $1,078.5 million as of December 31, 2022.

For further details see: